Regional brain MOR binding potential (BP) … using 11 C-carfentanil PET …before and during naltrexone treatment. Naltrexone inhibition of 11 C-carfentanil.

Slides:

Advertisements

Similar presentations

XR-NTX Implementation in Los Angeles County Desirée A. Crèvecoeur-MacPhail, PhD UCLA Integrated Substance Abuse Programs Santa Monica Blvd., Suite.

Advertisements

Drug Chemistry and Toxicology CHE 618 Alexander Nazarenko.

Cross-Talk Between Cannabinoid and Opioid Systems Steven R. Goldberg, Ph.D. Preclinical Pharmacology Section Behavioral Neuroscience Research Branch Intramural.

Investigating a Novel Neutral Antagonist, 6Beta-Naltrexol, in Alleviating Cocaine Withdrawal Symptoms Timothy DeYoung, Michelle Mueller, and Dr. Boyette-Davis.

Prevalence of Smoking in Psychiatric Disorders (PD) and Substance Abuse Disorders (SUD) Kalman D, Morrisette SB, and George, TP Am J Addiction, ,

Practical Applications Of Neuroscience Research February 16, 2007 Charles P. O’Brien, MD, PhD University of Pennsylvania Philadelphia VA Medical Center.

Disease X in 1985 No Data

T (B+F)/F B/F ‘late’ or ‘early’ image? whose brain is this? why a CT scan first? why increasing contrast w/ time? why increasing noise w/time?

Concepts for discussion 1.synopses – don’t overdo it 2.how comfortable were you with Wagner paper, Mintun, Farde? 3.non-specific vs specific binding 4.how.

ANALYSIS OF PET STUDIES Turku PET Centre V Oikonen PET Raw Data (sinogram) Results Parametric Sinogram PET Image Parametric Image Regional TACs.

Carboni, … DiChiara et al. J Neurosci 20:RC102(1-5), 2000 What do we know about addictive drugs from animal studies? “… cocaine, morphine, nicotine, and.

Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.

Goal:. design 11C-FLB457 perospirone Why? In the Arakawa paper, where does the baseline (aka ‘control’) data come from? From Vernaleken et al…

Prevalence of Alcohol Use Disorders

Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.

 1.A maladaptive pattern of substance use leading to significant impairment or distress. 2.Presence of two or more of the following symptoms within a.

BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.

Chapter 9: Opioid Analgesics

Lynda Sharrett-Field Addiction Therapy-2014 Chicago, USA August 4 - 6, 2014.

ADDICTION AND REWARD PARAMETERS IN PC2 NULL MICE Kabirullah Lutfy, Ph.D. Desean Lee, M.S.

Introduction ► College-student drinking remains a significant problem on campuses across the nation. ► It is estimated that 38-44% of college students.

Results of the Vivitrol Pilot in Los Angeles County Presented by: Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP.

Multiple Neuronal Systems Thought to be Involved in Nicotine Dependence Frank Vocci, Ph.D. Director Division of Treatment Research and Development National.

Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006

PHC 222 Part(I) Dr. Huda Al Salem Lecture (7). Factors that affect the efficacy 2- Concentration-Response Curves: Agonist Antagonist Partial agonist Desensetization.

PET determination of specific uptake of 11C-erlotinib by different tumor types expressing EGFR, in vivo, through kinetic modeling J. Ryan Petrulli1,4,

The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.

Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,

Module 1 General introduction to substitution treatment.

How antipsychotics work: Attaching to receptors and changing reality

MEDICINAL CHEMISTRY-III

Drug addiction – learning gone wild? Dr Stuart McLaren MRCPsych. Phase 1 Psychopharmacology module

Michael A. Nader, Paul W. Czoty, Susan H

HuBio 543 September 6, 2007 Frank F. Vincenzi

Department of Chemistry Seminar Announcement Date/Time/VenueTitle/Speaker 12 Jan (Wed) 11am – S8 Level 3 Executive Classroom PET in Neuroscience.

Opioids and Sucrose: Why do candy bars taste better than carrots? John Cadwallader.

A Revolution in Pain Pharmaceuticals 1. The Problem Opioids are the oldest and most prescribed pain drugs. They are the most powerful analgesics for treatment.

Reminder: What Information Will be Covered for EVERY Drug: What is drug? Why is it used? How is it administered? How much is used? Metabolism? Affects.

1 Psychology 320: Psychology of Gender and Sex Differences March 14 Lecture 55.

Buprenorphine {Suboxone®, Subutex®}

Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.

Dr. Laila M. Matalqah Ph.D. Pharmacology Pharmacodynamics 2 General Pharmacology M212.

Vivitrol (Naltrexone) Treatment for opioid addiction.

1 Use of Pharmacotherapies by Substance Abuse Treatment Facilities November 2007 Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration.

Pharmacodynamics What the drug does to the body?

Pharmacodynamics. * The study of the biochemical and physiologic effects of drugs and the molecular mechanisms by which those effects are produced * The.

Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.

One-Year Post-Treatment COMBINE Study Drinking Outcomes Dennis M. Donovan, Ph.D. for the COMBINE Study Research Group Research Society on Alcoholism Baltimore,

Turn in Problem set 4 Friday UNIT FIVE. Review: What is a monoamine? 1.A metabolic enzyme 2.A molecule with a CH 3 group on it 3.A molecule with an NH.

Gregory S. Brigham, Ph.D., CEO

Designing a Computer Simulation Tool for PET Neuroimaging

What does pharmacology have to do with treatment of heroin addiction?

5 Pharmacodynamics.

Opiate Receptors in the body

Assessment of [3H]Diprenorphine (DPN) and [11C]Carfentanil (CFN) to Endogenous Opioid Peptide (EOP) Release Darren R. Quelch1, Christine A. Parker1,2,

The Clinical Use of Cetirizine in the Treatment of Allergic Rhinitis

OK. What if we don’t care about the kinetics of a particular tracee molecule (e.g., glucose). Rather, we care about counting up the number of one type.

1. Introduction to Methadone

A Primer on Opioids/Opiates

Fig. 1. [11C]Martinostat images of all subjects show high cortical binding and distinct gray-white matter differences. [11C]Martinostat images of all subjects.

Drug antagonism Lab 7 Dr. Raz Mohammed

Lutz et al, Neuropsychopharmacology

Nat. Rev. Endocrinol. doi: /nrendo

Introduction to Pharmacology

Life expectancy and baseline BP: Male participants

Pharmacologic Interventions for Unhealthy Drinking

Introduction to Pharmacology

Medications used in Treatment of Alcohol and Drug Use Disorders

Medically assisted treatment

Presentation transcript:

Regional brain MOR binding potential (BP) … using 11 C-carfentanil PET …before and during naltrexone treatment. Naltrexone inhibition of 11 C-carfentanil BP was near maximal across all brain regions of interest with little variability across subjects.

Study Design

days of abstinence Study Design Naltrexone 11C-MeNTI 11C-Carfentanil 11C-MeNTI bolus

Occupancy of MOR by Naltrexone Weerts et al., 2008

Clinical doses of NTX occupy ~100% of MOR in (recently abstinent) alcoholics MOR = Mu Opiate Receptor Weerts et al., 2008 Individual Subjects

what are these images? not BP. why?

irreversible… means k4 = ? so BP = ? so is BP a good index to measure? Instead, we measure K1*k …. what does this represent? k2 + k3 what about this K1 * k k2 + k3 think probability…

Hmmm… If it ain’t MOR…and if it ain’t DOR… maybe its KOR? But to test it, we need a kappa-specific ligand.

Conclusions

Talbot et al., JNM, 2005

New Tracer Summary: [ 11 C]MKAP & [ 11 C]PKAB, KOR agonist & antagonist Yale PET Center Chemistry Autoloop (FxC) Radiochemical Yield: – mCi (EOS) – 5-7% High Specific Activity – > 10 EOS Low mass limit (0.01 µg/kg) Inject ~ 10 mCi New process Old process Specific Act. (n = 12) 0.96 ± 0.38 mCi/nmol Specific Act. (n = 30) 8.65 ± 3.14 mCi/nmol

New Tracer Summary: [ 11 C]MKAP & [ 11 C]PKAB, KOR agonist & antagonist Yale PET Center Activity summed from min post-injection from a male subject, normalized by injected dose. Cool Image MR PET

New Tracer for KOR Several OR radiotracers are currently available for PET in humans including 11 C-carfentanil, 11 C-diprenorphine, 11 C-buprenorphine, 18 F- cyclofoxy, and 11 C-naltrindole but none is selective for the KOR.

New Tracer Summary: [ 11 C]MKAP & [ 11 C]PKAB, KOR agonist & antagonist Yale PET Center Tracer Information KOR Antagonist Tracer name: [ 11 C]PKAB aka LY Endogenous ligand: Dynorphin

New Tracer Summary: [ 11 C]MKAP & [ 11 C]PKAB, KOR agonist & antagonist Yale PET Center Chemistry H 11 CN dppf, Pd 2 dba 3, KHCO 3 DMF, 80 °C, 5 min NaOH, H 2 O 2 80 °C, 5 min 11 CO 2 11 CH 4 NH 3, Pt 950 °C H 2, Ni 350 °C Cyanation Hydrolysis [ 11 C]PKAB Precursor Intermediate Radiochemical Yield: 81.0 ± 30.6 mCi (n = 14) Specific Activity (EOS): 1.18 ± 0.36 mCi/nmol (n = 14)

New Tracer Summary: [ 11 C]MKAP & [ 11 C]PKAB, KOR agonist & antagonist Yale PET Center Cool Image MR SRTM2_120 SRTM2_90 BP ND images for a single subject computed using the SRTM2 method and data of 120 and 90 min post-injection.

design ? GCRC ? 3$ 3$ 3$ 3$

Alcohol Self-Administration Model (O’Malley, Krishnan-Sarin et al., 2002) 4 pm Choice Block #1 5:00 pm Outpatient Treatment Priming Drink Alcohol Reactivity craving Ad-Lib Period 4 drinks per choice period (.015 g/dl) $12 tab per choice period (.03 g/dl) Naltrexone pretreatment Choice Block #2 6:00 pm 7 pm Day 0 Day 6 Day 7 MET Intervention Discharge

Get out some paper and a pen you design a PET study to test the finding(s) in Krishnan-Sarin et al.